Trials / Terminated
TerminatedNCT00097370
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label study of mepolizumab 750 mg intravenous in those subjects who participated in study 100185 to evaluate the long term safety and efficacy of mepolizumab in subjects with hypereosinophilic syndrome. The study will also evaluate the optimal dosing frequency for clinical use, the effects on corticosteroid reduction, and decrease of signs and symptoms of Hypereosinophilic Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mepolizumab | Study Drug |
Timeline
- Start date
- 2004-09-30
- Primary completion
- 2010-09-29
- Completion
- 2010-09-29
- First posted
- 2004-11-23
- Last updated
- 2017-07-07
- Results posted
- 2015-12-15
Locations
24 sites across 7 countries: United States, Australia, Belgium, Canada, France, Germany, Italy
Source: ClinicalTrials.gov record NCT00097370. Inclusion in this directory is not an endorsement.